InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.13
(
-0.09%
)
US TECH 100
19,203.20
(
-0.06%
)
Dow Jones
39,187.27
(
0.15%
)
Brent Oil
84.96
(
0.57%
)
Bitcoin
61,517.62
(
1.16%
)
Post# of 5181
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

TraderUsa

Send PM Follow Ignore
Followers 79
Posts 7854
Boards Moderated 2
Alias Born 05/05/2011

TraderUsa

Re: TraderUsa post# 2101

Saturday, 04/06/2013 8:34:03 AM

Saturday, April 06, 2013 8:34:03 AM

Post# of 5181
ONCS I like this part:

"The data presented were impressive. ImmunoPulse demonstrated a partial or complete response. ImmunoPulse treated patients showed a 68% and 45% percent of treated lesions demonstrated a durable response at three and six months, respectively.

To help our readers get an idea of the importance of these results, Amgen (Nasdaq: AMGN) is developing a treatment for melanoma that is currently in phase III trials. The first results provided by the company showed 16% of trial patients on the engineered virus had a durable response compared with 2% of those on the control therapy GM-CSF."

Source: http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html

Is my humble opinion.

Do not forget to go through this ihub :
http://investorshub.advfn.com/boards/board.aspx?board_id=20991

Gainers Nasdaq Stocks Traders

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up